GILD:NGS-Gilead Sciences Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 67.8

Change

+0.51 (+0.76)%

Market Cap

USD 98.10B

Volume

5.68M

Analyst Target

USD 77.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 246.77B
AMGN Amgen Inc

N/A

USD 160.19B
SNY Sanofi ADR

N/A

USD 118.11B
BIIB Biogen Inc

N/A

USD 32.82B
GRFS Grifols SA ADR

N/A

USD 6.19B
AMRN Amarin Corporation PLC

N/A

USD 0.32B
SCLX Scilex Holding Company

N/A

USD 0.20B
MIRA MIRA Pharmaceuticals Inc. Comm..

N/A

USD 0.01B
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing GILD

UBIO 7.77 % 0.95 %

N/A

N/A
BTEC:SW 7.01 % 0.00 %

N/A

N/A
XGEN:XETRA 4.08 % 0.00 %

N/A

N/A
XGES:LSE 4.08 % 0.00 %

N/A

N/A
JPHG:PA 3.90 % 0.00 %

N/A

N/A
JPHC:SW 3.90 % 0.00 %

N/A

N/A
JPHE:SW 3.90 % 0.00 %

N/A

N/A
JPHG:SW 3.90 % 0.00 %

N/A

N/A
JPHU:SW 3.90 % 0.00 %

N/A

N/A
JPNK:SW 3.90 % 0.00 %

N/A

N/A
JPNY:SW 3.90 % 0.00 %

N/A

N/A
CBUF:F 3.01 % 0.00 %

N/A

N/A
WHCS:SW 2.97 % 0.00 %

N/A

N/A
QUVU 2.05 % 0.00 %

N/A

N/A
DHSA:SW 1.96 % 0.00 %

N/A

N/A
DHS:SW 1.89 % 0.00 %

N/A

N/A
JIGB JPMorgan Corporate Bond R.. 0.41 % 0.14 %

N/A

USD 0.05B
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.30M
BSCK 0.00 % 0.10 %

N/A

N/A
BSCL 0.00 % 0.10 %

N/A

N/A
BSCQ Invesco BulletShares 2026.. 0.00 % 0.10 %

N/A

USD 3.21B
CBND 0.00 % 0.16 %

N/A

N/A
DVP 0.00 % 0.48 %

N/A

N/A
ESGW 0.00 % 0.40 %

N/A

N/A
FCY 0.00 % 0.84 %

N/A

N/A
FCY:CA 0.00 % 0.95 %

N/A

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.34B
IBCD 0.00 % 0.10 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD 0.26B
IVFVC 0.00 % 0.00 %

N/A

N/A
VSL 0.00 % 0.65 %

N/A

N/A
SPBO SPDR Portfolio Corporate .. 0.00 % 0.00 %

N/A

USD 1.44B
BTEC:LSE 0.00 % 0.00 %

N/A

N/A
BTEK:LSE 0.00 % 0.00 %

N/A

N/A
BTEE:LSE 0.00 % 0.00 %

N/A

N/A
RJZ 0.00 % 0.75 %

N/A

N/A
SCIU 0.00 % 0.19 %

N/A

N/A
SICK 0.00 % 0.95 %

N/A

N/A
XMS:CA iShares Edge MSCI Min Vol.. 0.00 % 0.33 %

N/A

CAD 0.04B
ZBIO 0.00 % 0.95 %

N/A

N/A
FCW:CA 0.00 % 0.90 %

N/A

N/A
DHS:LSE 0.00 % 0.00 %

N/A

N/A
DHSA:LSE 0.00 % 0.00 %

N/A

N/A
DHSD:LSE 0.00 % 0.00 %

N/A

N/A
DHSG:LSE 0.00 % 0.00 %

N/A

N/A
DHSP:LSE 0.00 % 0.00 %

N/A

N/A
MINV:LSE 0.00 % 0.00 %

N/A

N/A
MVOL:LSE 0.00 % 0.00 %

N/A

N/A
XFVT:LSE 0.00 % 0.00 %

N/A

N/A
XVTD:LSE 0.00 % 0.00 %

N/A

N/A
JPHC:PA 0.00 % 0.00 %

N/A

N/A
UBBB:PA 0.00 % 0.00 %

N/A

N/A
2B70:F 0.00 % 0.00 %

N/A

N/A
JP40:F 0.00 % 0.00 %

N/A

N/A
JP4H:F 0.00 % 0.00 %

N/A

N/A
WTD9:F 0.00 % 0.00 %

N/A

N/A
WTDY:F 0.00 % 0.00 %

N/A

N/A
WTEU:F 0.00 % 0.00 %

N/A

N/A
2B70:XETRA 0.00 % 0.00 %

N/A

N/A
JP40:XETRA 0.00 % 0.00 %

N/A

N/A
JP4H:XETRA 0.00 % 0.00 %

N/A

N/A
WTD9:XETRA 0.00 % 0.00 %

N/A

N/A
WTDY:XETRA 0.00 % 0.00 %

N/A

N/A
WTEU:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
HDLB ETRACS Monthly Pay 2xLeve.. 0.00 % 0.00 %

N/A

USD 0.01B
SCHJ Schwab 1-5 Year Corporate.. 0.00 % 0.00 %

N/A

USD 0.40B
HDIV 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.03B
GDOC Goldman Sachs ETF Trust 0.00 % 0.00 %

N/A

USD 0.03B
CSY9:XETRA 0.00 % 0.00 %

N/A

N/A
WDMVO:SW 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.31% 40% F 29% F
Dividend Return 0.95% 25% F 44% F
Total Return -15.36% 40% F 29% F
Trailing 12 Months  
Capital Gain -14.23% 67% D+ 36% F
Dividend Return 1.92% 25% F 28% F
Total Return -12.31% 67% D+ 37% F
Trailing 5 Years  
Capital Gain 1.36% 57% F 54% F
Dividend Return 18.90% 60% D- 77% C+
Total Return 20.26% 57% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 3.57% 78% C+ 57% F
Dividend Return 7.45% 78% C+ 62% D
Total Return 3.89% 100% F 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 17.50% 67% D+ 79% B-
Risk Adjusted Return 42.60% 67% D+ 75% C
Market Capitalization 98.10B 67% D+ 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 14% 7%
Price/Book Ratio 3.72 44% 29%
Price / Cash Flow Ratio 10.26 78% 25%
Price/Free Cash Flow Ratio 9.78 67% 27%
Management Effectiveness  
Return on Equity 2.39% 50% 62%
Return on Invested Capital 18.80% 80% 87%
Return on Assets 10.50% 100% 95%
Debt to Equity Ratio 101.93% 38% 22%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.